пресс-релиз

March 31, 2020

Cytocon DB 1.1 facilitates access of QSP modelers to baseline in vivo data in public domain

(Moscow - 31.03.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) platform development and provision, has released its new Cytocon DB 1.1. The name of the database derives from Cell and cYTOkine CONcentrations.

November 25, 2019

InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP), modeling and simulation for drug development, announced the launch of application ‘PK/RO simulator for anti-PD-1 mAbs’. The application is based on the model allowing to predict pharmacokinetics and target binding in human for therapeutic antibodies against PD-1 receptor.

October 1, 2018

InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP), modeling and simulation for drug development, announced today an extension of a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for QSP modeling in systemic lupus erythematosus (SLE). The goal is to support the clinical development of anifrolumab, an investigational monoclonal antibody against the type I interferon receptor, by modeling the contributions of key cell types involved in the pathophysiology of lupus that are associated with the type I interferon dysregulation commonly seen with the disease.

September 11, 2018

InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, today announced the launch of Alzheimer’s Disease (AD) Modeling Consortium. The aim of the consortium is the support of drug development in AD by consolidation of efforts of teams from various pharmaceutical companies in framework of development and application of AD QSP platform.

June 13, 2018

InSysBio LLC (www.insysbio.com), a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a collaboration with GSK, one of the world's leading research-based pharmaceutical and healthcare companies, for development of QSP platform of Chronic Obstructive Pulmonary Disease (COPD).